133 related articles for article (PubMed ID: 26049945)
1. Current state and limitations of daily oral therapy for treatment.
Solomon DA; Sax PE
Curr Opin HIV AIDS; 2015 Jul; 10(4):219-25. PubMed ID: 26049945
[TBL] [Abstract][Full Text] [Related]
2. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
3. [Consensus document of Gesida and Spanish Secretariat for the National Plan on AIDS (SPNS) regarding combined antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2012)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2012 Jun; 30(6):e1-89. PubMed ID: 22633764
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy in 1999 for antiretroviral-naive individuals with HIV infection.
Fischl MA
AIDS; 1999 Sep; 13 Suppl 1():S49-59. PubMed ID: 10546785
[TBL] [Abstract][Full Text] [Related]
5. Number of daily pills, dosing schedule, self-reported adherence and health status in 2010: a large cross-sectional study of HIV-infected patients on antiretroviral therapy.
Gianotti N; Galli L; Bocchiola B; Cahua T; Panzini P; Zandonà D; Salpietro S; Maillard M; Danise A; Pazzi A; Lazzarin A; Castagna A
HIV Med; 2013 Mar; 14(3):153-60. PubMed ID: 22994659
[TBL] [Abstract][Full Text] [Related]
6. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
[TBL] [Abstract][Full Text] [Related]
7. Once-daily highly active antiretroviral therapy for HIV-infected children: safety and efficacy of an efavirenz-containing regimen.
Scherpbier HJ; Bekker V; Pajkrt D; Jurriaans S; Lange JM; Kuijpers TW
Pediatrics; 2007 Mar; 119(3):e705-15. PubMed ID: 17308244
[TBL] [Abstract][Full Text] [Related]
8. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
Panel de expertos de GESIDA y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
[TBL] [Abstract][Full Text] [Related]
9. The role of rilpivirine in clinical practice: strengths and weaknesses of the new nonnucleoside reverse transcriptase inhibitor for HIV therapy.
Imaz A; Podzamczer D
AIDS Rev; 2012; 14(4):268-78. PubMed ID: 23258301
[TBL] [Abstract][Full Text] [Related]
10. The importance of treatment adherence in HIV.
Schaecher KL
Am J Manag Care; 2013 Sep; 19(12 Suppl):s231-7. PubMed ID: 24495293
[TBL] [Abstract][Full Text] [Related]
11. Daily dosing of highly active antiretroviral therapy.
Rosenbach KA; Allison R; Nadler JP
Clin Infect Dis; 2002 Mar; 34(5):686-92. PubMed ID: 11823957
[TBL] [Abstract][Full Text] [Related]
12. [Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults with human immunodeficiency virus infection (update February 2009)].
Panel de expertos de Gesida y Plan Nacional sobre el Sida
Enferm Infecc Microbiol Clin; 2009 Apr; 27(4):222-35. PubMed ID: 19246124
[TBL] [Abstract][Full Text] [Related]
13. [Data on rilpivirine in treatment-naïve patients. Lessons from ECHO, THRIVE and STaR].
Domingo P; Ribera E
Enferm Infecc Microbiol Clin; 2013 Jun; 31 Suppl 2():20-9. PubMed ID: 24252530
[TBL] [Abstract][Full Text] [Related]
14. Consequences of prior use of full-dose ritonavir as single protease inhibitor as part of combination antiretroviral regimens on the future therapy choices in HIV-1-infected children.
Feucht UD; Rossouw T; Van Dyk G; Forsyth B; Kruger M
Pediatr Infect Dis J; 2014 Feb; 33(2):e53-9. PubMed ID: 23958813
[TBL] [Abstract][Full Text] [Related]
15. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
[TBL] [Abstract][Full Text] [Related]
16. Initiation of antiretroviral therapy: implications of recent findings.
Saag MS
Top HIV Med; 2004; 12(3):83-8. PubMed ID: 15310939
[TBL] [Abstract][Full Text] [Related]
17. Treatment-for-prevention: clinical considerations.
Lockman S; Sax P
Curr Opin HIV AIDS; 2012 Mar; 7(2):131-9. PubMed ID: 22227588
[TBL] [Abstract][Full Text] [Related]
18. Predictors of clinically significant drug-drug interactions among patients treated with nonnucleoside reverse transcriptase inhibitor-, protease inhibitor-, and raltegravir-based antiretroviral regimens.
Patel N; Abdelsayed S; Veve M; Miller CD
Ann Pharmacother; 2011 Mar; 45(3):317-24. PubMed ID: 21386025
[TBL] [Abstract][Full Text] [Related]
19. Once-daily dosing of nevirapine in HAART.
Clotet B
J Antimicrob Chemother; 2008 Jan; 61(1):13-6. PubMed ID: 18006524
[TBL] [Abstract][Full Text] [Related]
20. A dose-ranging study to evaluate the antiretroviral activity and safety of amprenavir alone and in combination with abacavir in HIV-infected adults with limited antiretroviral experience.
Schooley RT; Clumeck N; Haubrich R; Thompson M; Danner SA; van Der Ende ME; Sereni D; Antunes F; Blake D; Myers RE; Tisdale M; Millard J; Mustafa N; Nacci P
Antivir Ther; 2001 Jun; 6(2):89-96. PubMed ID: 11491421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]